From 18 Months to 6: How Predictive Modeling Speeds Up Enzyme Discovery

Let's say you're managing a portfolio of off-patent APIs, and each needs a non-infringing manufacturing route before your competitors capture market share.

For generics manufacturers, the economics are brutal.

You need lower cost of goods sold, IP-ready processes, and fast go/no-go decisions across multiple molecules simultaneously.

Biocatalysis may be the solution to IP-protectable and profitable manufacturing, but finding the right enzyme, if there even is one, is not a straightforward process:

• • • Even if you know what enzyme family to use, finding the exact sequence for your problem is a gigantic step on its own if you’re not an expert in enzymes.
    • Conventional enzyme discovery scales linearly. More candidates mean more time, more reagents, and more cost. Unless you have robotic facilities screening 5,000-8,000 enzymes per week, you face an impossible bottleneck.

The good news? Predictive modeling flips this equation.

By simulating enzyme-substrate interactions digitally, you can evaluate 2 million potential candidates on a computer without consuming a single lab hour and then test only the 20 most promising routes in the lab.

This means you can work faster, make smarter investments earlier, and protect your IP while competitors are still running blind screens.

The Problem of Having Too Many Enzymes

Conducting enzyme screening without predictive modeling is like drug discovery without in silico tools: synthesizing and testing every molecule manually instead of modeling first.

When introducing biocatalysis into a chemical process, your first challenge is selection.

For a single reaction step, there may be hundreds of thousands of known enzyme sequences, dozens of enzyme families, and countless possible variations within a single wild type enzyme.

Testing these in a lab is costly and slow. Screening 200 enzymes doesn't just require 200 experiments. Each candidate demands cloning and expression, purification, activity testing, and data analysis. 

Traditional screening can test 500 to 8,000 enzymes per molecule over several months before you even know if the route is viable. Even for experienced teams, this effort consumes precious resources before you see meaningful results. You're forced to gamble on 1 or 2 molecules at most, hoping you chose correctly. While you're running trial and error experiments, your competitors are going to market filing patents. You need to accelerate your timeline in a way that also improves your chances of success.

How Predictive Modeling Cuts Discovery Times in Half

The good news is that enzyme discovery no longer needs to start in the lab.

Predictive modeling simulates enzyme-substrate interactions before any experimental work begins. Instead of testing hundreds of enzymes in the lab, you first evaluate them computationally, identifying which ones have the right molecular architecture to catalyze your specific transformation.

The hybrid approach of Zymvol’s Feasibility Engine combines physics-based molecular simulations that understand enzyme-substrate interactions at the atomic level with AI models trained on experimental data to predict performance trends.

This method allows you to evaluate thousands/millions of enzymes digitally without running 200 wet-lab experiments. Only the most promising candidates move forward to experimental validation.

A physics-first approach enables accurate prediction even for novel pharmaceutical substrates where AI would simply guess. Approaches that use sequence-only AI often struggle with pharmaceutical substrates because most pharma molecules are non-natural. They don't exist in AI training datasets. But simulations that take into consideration the physics and chemistry of the process deliver more than speed, by providing confidence and an atomic-level understanding of the process. Teams move forward knowing that experiments are guided by molecular insight, not guesswork. 

In a recent collaboration with multiple researchers using the BioMatchMaker® platform, over 450,000 ketoreductases were screened computationally, 16 candidates were recommended, and 50% showed the right activity. And all of this was accomplished in less than one month!

Evaluate Your Entire Portfolio Before Committing Lab Resources

Zymvol’s Feasibility Engine enables portfolio-wide evaluation across 15 to 20 molecules simultaneously.

In weeks, you can computationally assess enzymatic feasibility across your entire pipeline, identify which routes of synthesis are accessible to biocatalysis, and rank opportunities by technical probability and commercial priority. 

Backed by this assurance, you can commit lab resources only to routes flagged as high-probability. You can also pursue "yellow flag" routes knowing the risks upfront, and sometimes for defensive reasons: if computational modeling shows low probability but the molecule is strategically important, you can test it anyway, and if it fails, you've ruled out a potential competitive threat.

Many companies use feasibility assessment defensively: when you identify a route that won't work you know ahead of the market that there isn’t a threat on that particular route, at least not through biocatalysis. You can pivot early if a route shows low probability of success without wasting months trying to figure it out experimentally.

Your question shifts from "Can we afford to screen this molecule?" to "Does this molecule deserve our best resources?"

Predictive modeling allows you to screen many more enzymatic options in silico, identify alternative biocatalytic routes of synthesis, reduce lab workload dramatically, and reach proof-of-concept faster.

The result: better prioritization, faster execution, and fewer dead-end projects consuming your resources. 

When market conditions change, you can pivot quickly without sunk costs in failed experiments. When computational modeling says a route won't work, that's equally valuable intelligence. It protects you from competitor threats and prevents doomed investments.

Comparing Traditional and Predictive Approaches to Discovery

Let’s compare a typical enzyme discovery campaign.

Traditional approach:

• Screen 200-300 enzymes per discovery phase
• 12-24 months total (discovery, optimization, scale-up prep)
• Test 5,000-50,000+ enzymes across discovery and optimization
• High cost, uncertain outcome

Predictive modeling approach:

• Simulate hundreds of thousands of enzymes computationally
• Select 20-30 top candidates for focused lab work
• Optimize with fewer than 300 enzymes tested total
• 6-8 months to scale-ready enzyme

Predictive modeling reduces early development costs by approximately 90%. Timelines shrink by 50% as more molecules get evaluated in parallel with the same team size.

Just as importantly, starting with an enzyme that has been selected because of its predicted potential  (rather than hoping to find a random match among thousands) provides a massive advantage. And by the way, because the discovery is governed by physics-based simulations that optimize the enzyme-substrate interaction, your newly discovered enzyme faces fewer optimization cycles. Your teams focus on engineering iterations that work instead of repeated failures.

Smaller Teams Can Compete Without Building Infrastructure

Predictive modeling is especially powerful for companies with limited internal automated infrastructure. Rather than building large screening platforms with robotic high-throughput systems, you can compete immediately using computational screening to deliver small libraries that require no setup beyond standard analytical capabilities.

With predictive modeling, even teams with little background in biocatalysis can gain more data with clear insights to help them make better decisions. Computational predictions alongside Zymvol’s expert team provide the decision framework, and clear probability scores guide resource allocation. 

As projects progress, scientists learn which routes work—and why. Generics companies with limited or no enzyme experience achieve consistent success on "green light" routes and gain risk awareness on "yellow flag" routes. Teams making data-driven decisions can move faster than far larger organizations running expensive guesswork.

Predictive Modeling Makes Experimentation Smarter

In generics manufacturing, speed to market and cost efficiency determine your competitive advantage. Predictive modeling boosts that advantage by fundamentally changing how you allocate resources, manage risk, and design experiments.

By combining physics-based modeling with AI-driven prediction, you can simulate hundreds of thousands of enzyme candidates digitally, reduce months of lab screening to weeks, and accelerate the path from route design to industrial execution.

You can simulate first and invest later, preserving resources for molecules that truly justify scale-up. In enzyme development, the fastest route forward is knowing before testing where success is most likely.

When your competitors figure out predictive modeling, will you already hold the patent position? Or will you be months behind, still running experiments they've already ruled out computationally?

If you’re ready to transform how you approach your next project, speak with our team to request a demo.